<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-110267</identifier>
<setSpec>1135-2841</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">No disponible</dc:title>
<dc:description xml:lang="en">Objectives: To evaluate the cost-utility of statins in primary prevention of cardiovascular events in the Spanish population with a similar adherence to observational studies. Methods: Retrospective deterministic simulation model based on data of available statins in Spain. Various scenarios of cardiovascular risk were analyzed in a hypothetical population of adults with 60% adherence. The results were measured by cost per years of quality-adjusted life (QALYs). The analysis software used was TreeAge ®. Results: With a 10% risk at ages of 40 to 75 years, the cost-utility ratios for simvastatin 10 mg in men ranged from 33,452 to  4,430 &#128;/QALY, respectively and in women from 50,172 to 31,662 &#128;QALY, respectively. For other statins the costs were higher. Conclusions:  With low therapeutic adherence, the costs of statins in primary prevention were very high per additional QALY gained, especially at early ages and in women (AU)</dc:description>
<dc:creator>Rubio, Beltrán</dc:creator>
<dc:creator>Eduardo Ayala, L</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivos: Evaluar el coste-utilidad de las estatinas en prevención primaria de eventos cardiovasculares en población española con una adherencia similar a estudios observacionales. Métodos: Modelo de simulación determinístico retrospectivo basado en datos de estatinas disponibles en España. Se analizaron varios escenarios de riesgo cardiovascular en una población hipotética de adultos, con adherencia terapéutica del 60%. Los resultados se midieron en costes por años de vida ajustados por  calidad (AVACs). Se utilizó el software TreeAge®.Resultados: En hombres de 40 a 75 años con un riesgo del 10%, los ratios coste-utilidad para simvastatina 10 mg variaron de 33.452 a  4.430 &#128;/AVAC, respectivamente y en mujeres, de 50.172 a 31.662 &#128;/AVAC, respectivamente. Para el resto de estatinas los costes fueron superiores. Conclusiones: Con una baja adherencia terapéutica, los costes de las estatinas en prevención primaria fueron muy elevados por AVAC ganado adicional, especialmente en edades tempranas y en mujeres (AU)</dc:description>
<dc:source>Med. prev;18(2): 28-36, abr.-jun. 2012. ilus, tab</dc:source>
<dc:identifier>ibc-110267</dc:identifier>
<dc:title xml:lang="es">Análisis coste-utilidad de las estatinas en la prevención primaria de eventos cardiovasculares</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d30313</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d931^s22073</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d2359^s22054</dc:subject>
<dc:subject>^d33014^s22073</dc:subject>
<dc:subject>^d11758^s22018</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30152^s22083</dc:subject>
<dc:type>article</dc:type>
<dc:date>201206</dc:date>
</metadata>
</record>
</ibecs-document>
